Nectar Lifesciences Limited (NECLIFE.BO)
INR 44.02
(0.0%)
INR 44.02
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.35 Billion INR | -15.69% |
| 2022 | 7.53 Billion INR | -12.34% |
| 2021 | 8.59 Billion INR | -4.81% |
| 2020 | 9.03 Billion INR | 16.01% |
| 2019 | 7.78 Billion INR | -13.8% |
| 2018 | 9.03 Billion INR | -5.4% |
| 2017 | 9.55 Billion INR | 8.76% |
| 2016 | 8.78 Billion INR | -8.73% |
| 2015 | 9.62 Billion INR | 4.04% |
| 2014 | 9.24 Billion INR | 7.73% |
| 2013 | 8.58 Billion INR | -2.38% |
| 2012 | 8.79 Billion INR | -15.71% |
| 2011 | 10.43 Billion INR | 84.84% |
| 2010 | 5.64 Billion INR | -6.08% |
| 2009 | 6 Billion INR | -14.69% |
| 2008 | 7.04 Billion INR | 45.28% |
| 2007 | 4.84 Billion INR | 14.85% |
| 2006 | 4.22 Billion INR | 157.14% |
| 2005 | 1.64 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 6.35 Billion INR | -15.69% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 6.35 Billion INR | 0.0% |
| 2023 Q2 | 6.81 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 7.53 Billion INR | -12.34% |
| 2022 Q2 | 7.89 Billion INR | 0.0% |
| 2022 Q4 | 7.53 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 8.59 Billion INR | -4.81% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 8.59 Billion INR | 0.0% |
| 2021 Q2 | 7.95 Billion INR | 0.0% |
| 2020 Q2 | 7.83 Billion INR | 0.0% |
| 2020 FY | 9.03 Billion INR | 16.01% |
| 2020 Q4 | 9.03 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 7.78 Billion INR | -13.8% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 7.78 Billion INR | 0.0% |
| 2019 Q2 | 7.79 Billion INR | 0.0% |
| 2018 FY | 9.03 Billion INR | -5.4% |
| 2018 Q4 | 9.03 Billion INR | 0.0% |
| 2017 FY | 9.55 Billion INR | 8.76% |
| 2016 FY | 8.78 Billion INR | -8.73% |
| 2015 FY | 9.62 Billion INR | 4.04% |
| 2014 FY | 9.24 Billion INR | 7.73% |
| 2013 FY | 8.58 Billion INR | -2.38% |
| 2012 FY | 8.79 Billion INR | -15.71% |
| 2011 FY | 10.43 Billion INR | 84.84% |
| 2010 FY | 5.64 Billion INR | -6.08% |
| 2009 FY | 6 Billion INR | -14.69% |
| 2008 FY | 7.04 Billion INR | 45.28% |
| 2007 FY | 4.84 Billion INR | 14.85% |
| 2006 FY | 4.22 Billion INR | 157.14% |
| 2005 FY | 1.64 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -1701.407% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -36672.337% |
| Sigachi Industries Limited | 1.43 Billion INR | -344.27% |
| Bal Pharma Limited | 1.39 Billion INR | -355.097% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -3723.557% |
| Medico Remedies Limited | 80.5 Million INR | -7794.469% |
| Lasa Supergenerics Limited | 220.76 Million INR | -2778.83% |
| Venus Remedies Limited | 413.3 Million INR | -1437.712% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -939.307% |
| Alpa Laboratories Limited | 52.46 Million INR | -12013.529% |
| Shilpa Medicare Limited | 9.37 Billion INR | 32.201% |
| Aarti Drugs Limited | 5.64 Billion INR | -12.63% |
| Lupin Limited | 29.21 Billion INR | 78.248% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 90.44% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 20.973% |
| Windlas Biotech Limited | 36.41 Million INR | -17354.993% |
| Suven Life Sciences Limited | 7.09 Million INR | -89449.993% |
| Eris Lifesciences Limited | 27.81 Billion INR | 77.149% |
| Valiant Laboratories Limited | 767.08 Million INR | -728.509% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -68.283% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 37.169% |
| Ipca Laboratories Limited | 14.38 Billion INR | 55.815% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -536.554% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 80.586% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -90.952% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | -206.767% |
| Laurus Labs Limited | 25.77 Billion INR | 75.342% |
| Piramal Pharma Limited | 47.1 Billion INR | 86.507% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -776.764% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 84.199% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -23.848% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 48.369% |
| Unichem Laboratories Limited | 2.47 Billion INR | -156.768% |
| Sequent Scientific Limited | 4.87 Billion INR | -30.315% |
| Novartis India Limited | 69.7 Million INR | -9018.168% |
| Wanbury Limited | 1.16 Billion INR | -445.597% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -877.802% |
| Wockhardt Limited | 23.56 Billion INR | 73.025% |
| Themis Medicare Limited | 957.92 Million INR | -563.453% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -7008.112% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 82.655% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -3606.183% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 68.255% |
| Divi's Laboratories Limited | 30 Million INR | -21084.543% |
| NATCO Pharma Limited | 3.71 Billion INR | -71.211% |
| Gufic Biosciences Limited | 3.32 Billion INR | -90.9% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -1839.976% |
| Ind-Swift Limited | 10.13 Billion INR | 37.324% |
| Procter & Gamble Health Limited | 95.6 Million INR | -6547.869% |
| FDC Limited | 205.18 Million INR | -2997.382% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -228.562% |
| Granules India Limited | 13.15 Billion INR | 51.673% |
| Medicamen Biotech Limited | 308.17 Million INR | -1962.278% |
| Alkem Laboratories Limited | 14.18 Billion INR | 55.194% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -13721.415% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -144702.073% |
| Brooks Laboratories Limited | 56.41 Million INR | -11164.579% |
| Megasoft Limited | 1.47 Billion INR | -332.199% |
| ZIM Laboratories Limited | 1.08 Billion INR | -484.002% |
| Strides Pharma Science Limited | 25.16 Billion INR | 74.749% |
| Neuland Laboratories Limited | 953.89 Million INR | -566.253% |
| Morepen Laboratories Limited | 289.99 Million INR | -2091.565% |
| Hikal Limited | 8.17 Billion INR | 22.266% |
| Indoco Remedies Limited | 6.71 Billion INR | 5.421% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -122.8% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -1908.236% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -545.264% |
| Hester Biosciences Limited | 2.44 Billion INR | -160.063% |